Answers are grounded in this paper and cite their sources.
GRAZ-01-4 Introduction: The proprietary Salix extract, Assalix®, with 240 mg of salicin day−1 produced complete analgesia in 40% of patients with low back pain [1] and significant reduction of hip and knee pain [2]. We report some intermediary in vitro effects of Assalix® as well as reaffirming its overall clinical effectiveness. Methods: The effect of Assalix® on in vitro mediator release was assessed as previously described [3,4]. In open controlled clinical studies, 679 patients with acute exacerbation of low back pain consented to receive extract providing 120 mg salicin day−1 (W120, n = 115), 240 mg salicin day−1 (W240, n = 224) or conventional orthopaedic treatment (C, n = 335) that included rofecoxib (R) in 114 patients. The outcome was assessed after 4 weeks by the proportions of pain-free patients and by established indices of degree of pain relief. Results: In the in vitro studies, the approximate IC50 (μg mL−1) values of the extract were: PG-E2 (COX 1) undetectable; PG-E2 (COX 2) 50; TNFα 200, IL1β 110; IL6 200; of salicylate PG E2 (COX 1) undetectable, PG E2 (COX 2) 16 (salicin alone had no effect). In the clinical studies, 40% of the patients in W240, 19% in W120 and 18% in C were pain-free after 4 weeks of treatment. The pain index improved by 36% (W240), 18% (W120) and 25% (C), respectively. Treatment with Assalix® was significantly cheaper than conventional treatment. Multivariable modelling to examine for possible confounding effects of duration and severity of initial pain tended to identify W240 as an independent explanator of better pain relief than C. Treatment outcomes in W240 and R were similar. No specific adverse effects of Assalix® were observed except occasional allergic skin reactions. Conclusions: Assalix® is a potent and selective inhibitor of COX 2 and a weak inhibitor of cytokine release. The high benefit-risk ratio supports its use in preference to non-selective NSAIDs in the treatment of osteoarthritic pain and as an economically sound alternative to expensive conventional treatments.
No takes yet. Share an insight, caveat, or question.
Chrubasik et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: